204 related articles for article (PubMed ID: 36052413)
1. Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs.
Wildenthal JA; Atkinson A; Lewis S; Sayood S; Nolan NS; Cabrera NL; Marschall J; Durkin MJ; Marks LR
Clin Infect Dis; 2023 Feb; 76(3):487-496. PubMed ID: 36052413
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections.
Marks LR; Liang SY; Muthulingam D; Schwarz ES; Liss DB; Munigala S; Warren DK; Durkin MJ
Clin Infect Dis; 2020 Dec; 71(10):e650-e656. PubMed ID: 32239136
[TBL] [Abstract][Full Text] [Related]
3. One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review.
Acheson LS; Siefried KJ; Clifford B; Murray E; Steele M; Clague L; Malone V; Roberts DM; Ferguson LJ; Matthews GV; Ezard N
Int J Infect Dis; 2021 Nov; 112():63-65. PubMed ID: 34520844
[TBL] [Abstract][Full Text] [Related]
4. Community-Acquired Staphylococcus aureus Bacteremia Among People Who Inject Drugs: A National Cohort Study in England, 2017-2020.
McGuire E; Collin SM; Brown CS; Saito M
Clin Infect Dis; 2024 Jun; 78(6):1443-1450. PubMed ID: 38315893
[TBL] [Abstract][Full Text] [Related]
5. Early switch/early discharge opportunities for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections in Brazil.
Furtado GH; Rocha J; Hayden R; Solem C; Macahilig C; Tang WY; Chambers R; Figueiredo MLN; Johnson C; Stephens J; Haider S
Braz J Infect Dis; 2019; 23(2):86-94. PubMed ID: 31078574
[TBL] [Abstract][Full Text] [Related]
6. Oral antibiotic therapy in people who inject drugs (PWID) with bacteraemia.
Martinez AE; Scheidegger C; Bättig V; Erb S
Swiss Med Wkly; 2020 Jun; 150():w20259. PubMed ID: 32564343
[TBL] [Abstract][Full Text] [Related]
7. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.
Heldman AW; Hartert TV; Ray SC; Daoud EG; Kowalski TE; Pompili VJ; Sisson SD; Tidmore WC; vom Eigen KA; Goodman SN; Lietman PS; Petty BG; Flexner C
Am J Med; 1996 Jul; 101(1):68-76. PubMed ID: 8686718
[TBL] [Abstract][Full Text] [Related]
8. Patients With Serious Injection Drug Use-Related Infections who Experience Patient-Directed Discharges on Oral Antibiotics Have High Rates of Antibiotic Adherence but Require Multidisciplinary Outpatient Support for Retention in Care.
Lewis S; Liang SY; Schwarz ES; Liss DB; Winograd RP; Nolan NS; Durkin MJ; Marks LR
Open Forum Infect Dis; 2022 Feb; 9(2):ofab633. PubMed ID: 35106316
[TBL] [Abstract][Full Text] [Related]
9. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.
Donnelly D; Pillinger KE; Debnath A; DePasquale W; Munsiff S; Louie T; Jones CMC; Shulder S
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S40-S48. PubMed ID: 38465838
[TBL] [Abstract][Full Text] [Related]
10. The Influence of the Route of Antibiotic Administration, Methicillin Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection.
McNeil JC; Kaplan SL; Vallejo JG
Pediatr Infect Dis J; 2017 Jun; 36(6):572-577. PubMed ID: 28027279
[TBL] [Abstract][Full Text] [Related]
11. Microbiology and initial antibiotic therapy for injection drug users and non-injection drug users with cutaneous abscesses in the era of community-associated methicillin-resistant Staphylococcus aureus.
Jenkins TC; Knepper BC; Jason Moore S; Saveli CC; Pawlowski SW; Perlman DM; McCollister BD; Burman WJ
Acad Emerg Med; 2015 Aug; 22(8):993-7. PubMed ID: 26202847
[TBL] [Abstract][Full Text] [Related]
12. Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes.
Priest DH; Peacock JE
South Med J; 2005 Sep; 98(9):854-62. PubMed ID: 16217976
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.
Thorlacius-Ussing L; Andersen CØ; Frimodt-Møller N; Knudsen IJD; Lundgren J; Benfield TL
Trials; 2019 May; 20(1):250. PubMed ID: 31046810
[TBL] [Abstract][Full Text] [Related]
16. The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated Staphylococcus aureus bacteremia.
Pérez-Rodríguez MT; Sousa A; Moreno-Flores A; Longueira R; Diéguez P; Suárez M; Lima O; Vasallo FJ; Álvarez-Fernández M; Crespo M
Int J Infect Dis; 2021 Jan; 102():554-560. PubMed ID: 33157291
[TBL] [Abstract][Full Text] [Related]
17. Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive Staphylococcus aureus Infections: Opportunities for Improvement.
Appa A; Adamo M; Le S; Davis J; Winston L; Doernberg SB; Chambers H; Martin M; Hills NK; Coffin P; Jain V
Am J Med; 2022 Jan; 135(1):91-96. PubMed ID: 34508704
[TBL] [Abstract][Full Text] [Related]
18. Significantly lower 30 day/inpatient mortality observed in people who inject drugs (PWID) compared to non-PWID with Staphylococcus aureus bacteraemia.
Mortimer I; Drury K; Lowe S; Akhtar M; Barlow GD; Easom N; Lillie PJ
J Infect; 2022 Oct; 85(4):436-480. PubMed ID: 35724756
[No Abstract] [Full Text] [Related]
19. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial.
del Río A; Gasch O; Moreno A; Peña C; Cuquet J; Soy D; Mestres CA; Suárez C; Pare JC; Tubau F; Garcia de la Mària C; Marco F; Carratalà J; Gatell JM; Gudiol F; Miró JM;
Clin Infect Dis; 2014 Oct; 59(8):1105-12. PubMed ID: 25048851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
